These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37400299)

  • 1. Hyperbilirubinemia and Gilbert's syndrome in Cystic Fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor.
    Terlizzi V; Timpano S; Salvi M; Tosco A; Castaldo A; Fevola C; Leonetti G; Vitullo P; Sepe A; Badolato R; Salvatore D
    J Cyst Fibros; 2023 Nov; 22(6):1130-1132. PubMed ID: 37400299
    [No Abstract]   [Full Text] [Related]  

  • 2. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert's syndrome.
    Weitzel J; Welsner M; Taube C; Ballmann M; Sutharsan S
    BMC Pulm Med; 2024 Jul; 24(1):307. PubMed ID: 38956524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regarding the article entitled "Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis".
    Hoo ZH; Lai LY; Sandler RD; Daniels TE; Dawson S; Hutchings M; Wildman MJ
    J Cyst Fibros; 2023 May; 22(3):587. PubMed ID: 36948912
    [No Abstract]   [Full Text] [Related]  

  • 6. Triple Therapy for Cystic Fibrosis
    Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
    N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis.
    McKinzie CJ; Doligalski CT; Lobritto SJ; Coakley RD; Gower WA
    J Cyst Fibros; 2022 Mar; 21(2):227-229. PubMed ID: 34384711
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor.
    Meltzer LJ; Gross JE
    J Cyst Fibros; 2024 Jan; 23(1):132-136. PubMed ID: 37210228
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence of adverse events in cystic fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor: Experience of the regional referral center in Tuscany, Italy.
    Manciulli T; Bresci S; Mencarini J; Avarello A; Taccetti G; Terlizzi V
    Pediatr Pulmonol; 2023 Dec; 58(12):3626-3629. PubMed ID: 37750598
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor.
    Lowry S; Mogayzel PJ; Oshima K; Karnsakul W
    J Cyst Fibros; 2022 Mar; 21(2):e99-e101. PubMed ID: 34275759
    [No Abstract]   [Full Text] [Related]  

  • 11. Gilbert's syndrome leads to elevated bilirubin after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
    Patel N; Ansar M; Pham A; Thomsen K; McKinzie CJ; Polineni D; Esther CR; Brown RF
    Pediatr Pulmonol; 2024 Apr; 59(4):863-866. PubMed ID: 38179880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
    Hudson BN; Jacobs HR; Philbrick A; Zhou XA; Simonsen MM; Safirstein JA; Rotolo SM
    J Cyst Fibros; 2022 Nov; 21(6):1066-1069. PubMed ID: 36088208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: What consequences on Aspergillus-related diseases? Preliminary insights.
    Chesnay A; Bailly É; Cosson L; Flament T; Desoubeaux G
    J Cyst Fibros; 2022 Nov; 21(6):1084-1085. PubMed ID: 36151024
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
    Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE;
    J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
    Schwarz C; Sutharsan S; Epaud R; Klingsberg RC; Fischer R; Rowe SM; Audhya PK; Ahluwalia N; You X; Ferro TJ; Duncan ME; Bruinsma BG
    J Cyst Fibros; 2021 Mar; 20(2):228-233. PubMed ID: 32586736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis.
    De Vuyst RC; Bennard E; Kam CW; McKinzie CJ; Esther CR
    Pediatr Pulmonol; 2023 May; 58(5):1592-1594. PubMed ID: 36718851
    [No Abstract]   [Full Text] [Related]  

  • 19. Outcome of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis and solid organ transplantation.
    Ørum MB; Rönsholt FF; Jeppesen M; Bendstrup E; Katzenstein TL; Ott P; Perch M; Pressler T; Qvist T; Jensen-Fangel S
    Pediatr Pulmonol; 2023 Feb; 58(2):602-605. PubMed ID: 36314653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding.
    Jain R; Wolf A; Molad M; Taylor-Cousar J; Esther CR; Shteinberg M
    J Cyst Fibros; 2022 Nov; 21(6):1074-1076. PubMed ID: 36266182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.